文献速递腹部MR

钆贝葡胺增强MRI与钆塞酸增强MRI检测肝细胞癌的比较:基于LI-RADS 2018版的前瞻性个体内随机研究

Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
PubMed 文献 · AJR Am J Roentgenol · 2021-11-24

前瞻性个体内随机研究纳入126例肝细胞癌高危患者,分别行钆贝葡胺与钆塞酸3-T肝脏MRI。钆贝葡胺对肝细胞癌的敏感度高于钆塞酸,无论仅用动态期还是联合肝胆期;钆贝葡胺的增益在小肝癌更明显。肝胆期可提高两种对比剂的敏感度,但仅用动态期的钆贝葡胺敏感度仍优于联合肝胆期的钆塞酸。

要点

  • 钆贝葡胺增强MRI对肝细胞癌的敏感度高于钆塞酸增强MRI。
  • 联合肝胆期可提高两种对比剂的敏感度,小肝癌增益更明显。
  • 仅用动态期的钆贝葡胺敏感度优于联合肝胆期的钆塞酸。

核心结论

  • 钆贝葡胺对肝细胞癌的敏感度高于钆塞酸,仅用动态期或联合肝胆期均如此;钆贝葡胺的敏感度增益在小肝癌更明显;肝胆期提高两种对比剂的敏感度,但仅用动态期的钆贝葡胺敏感度仍优于联合肝胆期的钆塞酸。

研究设计与样本

  • 前瞻性个体内随机研究,纳入126例肝细胞癌高危患者(男112例、女14例,平均年龄52.3岁),分别行钆贝葡胺(0.05 mmol/kg)与钆塞酸(0.025 mmol/kg)3-T肝脏MRI,两次检查间隔7-14天,对比剂顺序随机;所有检查均包括增强后动态期和肝胆期(钆贝葡胺120分钟、钆塞酸20分钟);以组织学确诊肝细胞癌(n=96)为参考标准。

诊断标准与关键数值

  • 三位放射科医师独立阅片,采用LI-RADS 2018版分类,并采用将肝胆期低信号从LR-4升级为LR-5的LI-RADS修改版;LR-5视为肝细胞癌阳性。仅用动态期时,各阅片者钆贝葡胺敏感度74.0-80.2% vs 钆塞酸54.2-67.7%;联合动态期和肝胆期时,钆贝葡胺82.1-87.4% vs 钆塞酸66.3-81.1%。1.0-2.0 cm肝细胞癌仅用动态期时,钆贝葡胺敏感度61.9%(所有阅片者)vs 钆塞酸38.1-57.1%;联合动态期和肝胆期时,钆贝葡胺76.2-85.7% vs 钆塞酸52.4-61.9%。各阅片者、对比剂和图像集的阳性预测值范围为88.6%-97.4%。

临床应用与阅片要点

  • 作者认为,对肝细胞癌高危患者行肝脏MRI时,钆贝葡胺是优于钆塞酸的对比剂选择;肝胆期图像可提高两种对比剂的诊断敏感度。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Gadobenate and gadoxetate show different degrees of intracellular accumulation within hepatocytes, potentially impacting these agents' relative performance for hepatocellular carcinoma (HCC) diagnosis. OBJECTIVE. The purpose of this article was to perform an intraindividual comparison of gadobenate-enhanced MRI and gadoxetate-enhanced MRI for detection of HCC and to assess the impact of inclusion of hepatobiliary phase images on HCC detection for both agents. METHODS. This prospective study enrolled 126 patients (112 men, 14 women; mean age, 52.3 years) at high risk for HCC who consented to undergo two 3-T liver MRI examinations (one using gadobenate [0.05 mmol/kg], one using gadoxetate [0.025 mmol/kg]) separated by 7-14 days. The order of the two contrast agents was randomized. All examinations included postcontrast dynamic and hepatobiliary phase images (120 minutes for gadobenate, 20 minutes for gadoxetate). Three radiologists independently reviewed the gadobenate and gadoxetate examinations in separate sessions and recorded the location of detected observations. Observations were classified using LI-RADS version 2018 and using a LI-RADS modification whereby hepatobiliary phase hypointensity may upgrade observations from category LR-4 to LR-5. Observations classified as LR-5 were considered positive interpretations for HCC. Diagnostic performance for histologically confirmed HCC (n = 96) was assessed. RESULTS. Across readers, sensitivity for HCC for gadobenate versus gadoxetate was 74.0-80.2% versus 54.2-67.7% using dynamic images alone and 82.1-87.4% versus 66.3-81.1% using dynamic and hepatobiliary phase images. For HCCs measuring 1.0-2.0 cm, sensitivity for gadobenate versus gadoxetate was 61.9% (all readers) versus 38.1-57.1% using dynamic images alone and 76.2-85.7% versus 52.4-61.9% using dynamic and hepatobiliary phase images. PPV for HCC ranged from 88.6% to 97.4% across readers, agents, and image sets. CONCLUSION. Sensitivity for HCC was higher for gadobenate than for gadoxetate, whether using dynamic images alone or dynamic and hepatobiliary phase images; the improved sensitivity using gadobenate was more pronounced for small HCCs. Whereas hepatobiliary phase images improved sensitivity for both agents, sensitivity of gadobenate using dynamic images alone compared favorably with that of gadoxetate using dynamic and hepatobiliary phase images. CLINICAL IMPACT. The findings support gadobenate as a preferred agent over gadoxetate when performing liver MRI in patients at high risk for HCC.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Rong, He, Tang, et al. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study. AJR Am J Roentgenol. 2021. PMID: 34817191. doi:10.2214/AJR.21.26818

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。